News Image

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Provided By GlobeNewswire

Last update: Nov 23, 2024

- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes

Read more at globenewswire.com

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (2/21/2025, 8:02:48 PM)

After market: 36.85 0 (0%)

36.85

+0.05 (+0.12%)



Find more stocks in the Stock Screener

Follow ChartMill for more